Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy

Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1999, Pages 373-384

  Grasela, Thaddeus H ^a   Fiedler Kelly, Jill ^a   Cox, Eugène ^b   Womble, Gilda P ^c   Risner, Marcus E ^c   Chen, Chao ^c  

^a Pharmaceutical Outcomes Res Inc   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ACETYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSFORMATION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TRIAZINES;

EID: 0032937202     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007949     Document Type: Article

References (32)

1. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW: Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-541.
2. Yuen WC, Peck AW: Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988;26:242P.
3. Posner J, Holdich T, Crome P: Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-128.
4. Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E: Pharmacokinetics of lamotrigine with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993;19(1):25-32.
5. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, et al: Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
6. Posner J, Cohen AF, Land G, Winton C, Peck AW: The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaenemia (Gilbert's syndrome). Br J Clin Pharmacol 1989;28:117-120.
7. Hussein Z, Posner J: Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-465.
8. Colucci R, Glue P, Holt B, Banfield C, Reidenberg P, Meehan JW, et al: Effects of Felbamate on the pharmacokinetics of lamotrigine. J Clin Pharmacol 1996;36:624-628.
9. Hamilton MJ, Cohen AF, Yuen AWC, Harkin N, Land G, Weatherley BC, et al: Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993;34(1):166-173.
10. Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, et al: Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60:145-156.
11. Beal SL, Sheiner LB: The NONMEM system. Am Stat 1980;34:118.
12. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al: Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-2291.
13. Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al: Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35(1):113-121.
14. Schachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL, et al: Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 1995;8:201-209.
15. Sailstad JM, Findlay JWA: Immunofluorometric assay for lamotrigine (Lamictal®) in human plasma. Ther Drug Monit 1991;13:433-442.
16. Lamotrigine (Lamictal®) product information. 1998 Glaxo Wellcome, Inc.
17. Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, Mullen PW, et al: Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983;8:355-364.
18. Benet LZ, Oie S, Schwartz JB: Design and optimization of dosage regimen: pharmacokinetic data. In, Gilman AG, Roll TW, Nies AS, Taylor P (eds.): The Pharmacological Basis of Therapeutics, 9th ed. New York: Pergamon, 1996:1771.
19. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A: Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
20. Trnavska Z, Krejcova H, Tkaczykovam, Salcmanova Z, Elis J: Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva. Eur J Drug Metab & Pharmacokinet 1991;3:211-215.
21. Wood AJJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20(5):350-373.
22. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG, de Korte RA, Meiher JW, Meinardi H, et al: Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-254.
23. Yuen AWC, Land G, Weatherley BC, Peck AW: Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-513.
24. Posner J, Webster H, Yuen WC: Investigation of the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes. Br J Clin Pharmacol 1991;32:658P.
25. Sander JWAS, Trevisol-Bittencourt PPC, Hart YM, Patsalos PN: The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990;7:226-229.
26. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC: A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-226.
27. Graves NM, Ritter FJ, Wagner ML, Floren KL, Alexander BJ, Campbell JI, et al: Effect of lamotrigine on carbamazepine epoxide concentrations. Epilepsia 1991;32:13.
28. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS: Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11:147-150.
29. Pisani F, Russo M, Trio R, Artesi C, Fazio A, Oteri G, et al: Lamotrigine in refractory epilepsy: a long-term open study. In, Pisani F, Perucca E, Avanzini G, Richens A (eds.): New Antiepileptic Drugs. Amsterdam: Elsevier, 1991;187-191.
30. Schapel GT, Dollman W, Beran RG, Dunagan FM: No effect of LTG on CBZ and CBZ-E concentrations. Epilepsia 1991;32(Suppl. 1):S58.
31. Brodie MJ, Richens A, Yuen AWC: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479.
32. Holdich T, Whiteman P, Orme M, Back D, Ward S: Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 1991;32(Suppl. 1):96.